NCT03318887View on ClinicalTrials.gov

Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

February 1, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir/daclatasvir with or without ribavirin

Direct-acting antiviral treatment for hepatitis C virus infection

Trial Locations (1)

Unknown

Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03318887 - Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA | Biotech Hunter | Biotech Hunter